eMedicine Specialties > General Surgery > Abdomen

Chyle Fistula

Author: Deron J Tessier, MD, Staff Surgeon, Kaiser Permanente Medical Center, Fontana, CA
Coauthor(s): Russell A Williams, MBBS, Program Director, Professor, Department of Surgery, University of California Medical Center at Irvine
Contributor Information and Disclosures

Updated: Jan 10, 2008

Introduction

Chyle fistula is defined as a leakage of lymphatic fluid from the lymphatic vessels, typically accumulating in the thoracic or abdominal cavities, but occasionally manifesting as an external fistula. Chyle fistula is a rare but potentially devastating and morbid condition. First described in the 17th century as complications of trauma, chyle fistulas most commonly occur secondary to lymphatic disease or malignancy or following abdominal, neck, or thoracic operations. Chyle fistulas also can form as a result of venous hypertension, and they have been described in patients with superior vena cava syndrome or thrombosis of the vena cava, among others.

History of chyle fistulas

  • 17th century: Trauma is recognized as a primary cause of chylous fistulas.
  • 1627: Asellius first describes chyle from the mesenteric vessels of a dog.
  • 1691: Morton describes chylous ascites after performing paracentesis in an 18-month-old child.
  • 1854: Virchow publishes an account of chylous ascites in a newborn calf with occlusion of the subclavian vein.

History of the Procedure

Patients with chyle fistulas usually give histories of some comorbid conditions such as malignancy or prior operations in the chest, neck, or abdomen. In postoperative patients, symptoms become evident after the start of oral feeding and depend on the site of obstruction.

Problem

Chyle fistulas can be extremely morbid due to loss of fluids, electrolytes, and other nutrients. In addition, chyle fistulas can result in loss of lymphocytes and immune dysfunction. Finally, chyle fistulas are space-filling and exert pressure on surrounding tissues, creating symptoms that can range from minimal discomfort to life-threatening situations.

Frequency

Chyle fistulas are rare events. Typical causes include lymphatic disease; malignancy; trauma; and postoperative trauma following abdominal, neck, or thoracic operations. Postoperatively, approximately 75% of chyloperitoneum cases occur after abdominal aortic aneurysm repair, 19% after aortofemoral bypass, and 7% after resection of infected aortic grafts.

Etiology

The most common causes of chyle fistulas include subclavian vein thrombosis, malignant invasion of the lymphatics, inflammatory reactions (ie, tuberculosis, pancreatitis, cirrhosis, adhesions, pulmonary fibrosis), and prior surgeries near the cisterna chyli or thoracic duct.

Pathophysiology

Leakage of lymph from damaged lymph vessels is common after surgery or trauma. However, damaged lymphatics most often heal spontaneously or direct lymph centrally via rich interconnected lymphatic collaterals, without any significant morbidity. For chyle fistulas to form, either a scarcity of lymphatic collaterals must be present or the injury to the lymphatic channels must overwhelm the remaining lymphatic vessels. In addition, abnormal lymphatic vessels may be incapable of adequate lymph flow, leading to the accumulation of chyle.

Chyle flow varies dramatically depending on the quantity and quality of oral intake. During times of starvation, chyle flow is minimal. After meals, especially those with high contents of long-chain fatty acids, chyle flow increases dramatically. This basic knowledge provides the rationale for controlling dietary intake as part of the treatment of this disease.

Presentation

Because of the relatively low incidence of chyle fistulas, a high index of suspicion is required to make a timely diagnosis. Diagnosis usually is made after the patient has recovered from the injury and has started eating.

Symptoms of chyloperitoneum include (1) nausea, (2) vomiting, (3) early satiety or anorexia, (4) abdominal discomfort or pain, and (5) dyspnea due to chylous fluid causing abdominal distention and pressure on the visceral structures and diaphragm.

Symptoms of chylothorax include (1) shortness of breath, (2) pleural effusion, and (3) decreased cardiac preload due to a mediastinal shift from a large chylothorax.

Indications

Characteristics of thoracentesis or paracentesis aspirate

  • Odorless
  • Milky appearance that separates into a creamy layer when left to stand
  • Specific gravity greater than 1.012
  • Total fat composition of 0.4-4 g/L
  • Total protein greater than 30 g/L
  • pH greater than 7.0
  • Sterile fluid
  • Lipophilic globules when stained with Sudan III
  • WBC differential of predominately lymphocytes

Relevant Anatomy

The cisterna chyli and thoracic duct drain lymph from the entire body except the head, neck, arms, and right thorax (which instead use the right bronchomediastinal, jugular, and subclavian lymph trunks to form the right lymph duct). The anatomy is highly variable, with 50% of people not having an identifiable cisterna chyli. In addition, half of the 4 liters of lymph draining through the cisterna chyli and thoracic duct originates from the intestinal and hepatic lymphatics.

The cisterna chyli is found on the posterolateral edge to the right of the aorta at the level of vertebral bodies T12, L1, L2, and L3 as lymphatics from the mesentery, intercostal, and lumbar regions coalesce in the retroperitoneal space.

At approximately L1, the cisterna chyle ascends, becoming the thoracic duct. The duct then enters the posterior mediastinum, crosses at T4 into the left retropleural space, and continues in a cephalad direction. The thoracic duct then enters the venous system at the junction of the left subclavian and internal jugular veins (see Media file 1).

Contraindications

Contraindications to surgical correction of chyle fistulas are based on the patient's comorbidities and his or her ability to tolerate surgery.

More on Chyle Fistula

Overview: Chyle Fistula
Treatment: Chyle Fistula
Follow-up: Chyle Fistula
Multimedia: Chyle Fistula
References

References

  1. Browse NL, Allen DR, Wilson NM. Management of chylothorax. Br J Surg. Dec 1997;84(12):1711-6. [Medline].

  2. Cerfolio RJ, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Postoperative chylothorax. J Thorac Cardiovasc Surg. Nov 1996;112(5):1361-5; discussion 1365-6. [Medline].

  3. de Vries GJ, Ryan BM, de Bievre M, Driessen A, Stockbrugger RW, Koek GH. Cirrhosis related chylous ascites successfully treated with TIPS. Eur J Gastroenterol Hepatol. Apr 2005;17(4):463-6. [Medline].

  4. Gunnlaugsson CB, Iannettoni MD, Yu B, Chepeha DB, Teknos TN. Management of chyle fistula utilizing thoracoscopic ligation of the thoracic duct. ORL J Otorhinolaryngol Relat Spec. 2004;66(3):148-54. [Medline].

  5. Hashim SA, Roholt JB, Babayan VK. Treatment of chyluria and chylothorax with medium chain triglycerides. N Engl J Med. 1964;270:276.

  6. Hayden JD, Sue-Ling HM, Sarela AI, Dexter SP. Minimally invasive management of chylous fistula after esophagectomy. Dis Esophagus. 2007;20(3):251-5. [Medline].

  7. Ikard RW. Iatrogenic chylous ascites. Am Surg. Aug 1972;38(8):436-8. [Medline].

  8. Mincher L, Evans J, Jenner MW, Varney VA. The successful treatment of chylous effusions in malignant disease with octreotide. Clin Oncol (R Coll Radiol). Apr 2005;17(2):118-21. [Medline].

  9. Nix JT, Albert M, Dugas JE. Chylothorax and chylous ascites: a trial of 302 selected cases. Amer J Gastroenterol. 1957;28:40.

  10. Nyquist GG, Hagr A, Sobol SE, Hier MP, Black MJ. Octreotide in the medical management of chyle fistula. Otolaryngol Head Neck Surg. Jun 2003;128(6):910-1. [Medline].

  11. Pabst TS 3rd, McIntyre KE Jr, Schilling JD, Hunter GC, Bernhard VM. Management of chyloperitoneum after abdominal aortic surgery. Am J Surg. Aug 1993;166(2):194-8; discussion 198-9. [Medline].

  12. Podnos YD, Williams RA, Wilson SE. Management of chylothorax and chyloperitoneum after aortic reconstruction. Curr Ther Vascul Surg. 1999;3.

  13. Press OW, Press NO, Kaufman SD. Evaluation and management of chylous ascites. Ann Intern Med. Mar 1982;96(3):358-64. [Medline].

  14. Seelig MH, Klingler PJ, Oldenburg WA. Treatment of a postoperative cervical chylous lymphocele by percutaneous sclerosing with povidone-iodine. J Vasc Surg. Jun 1998;27(6):1148-51. [Medline].

  15. Vasko JS, Tapper RI. The surgical significance of chylous ascites. Arch Surg. Sep 1967;95(3):355-68. [Medline].

  16. Williams RA, Vetto J, Quiñones-Baldrich W, Bongard FS, Wilson SE. Chylous ascites following abdominal aortic surgery. Ann Vasc Surg. May 1991;5(3):247-52. [Medline].

Further Reading

Keywords

chyle fistulas, chylous ascites, chylothorax, chyloperitoneum, lymphatic fluid leakage

Contributor Information and Disclosures

Author

Deron J Tessier, MD, Staff Surgeon, Kaiser Permanente Medical Center, Fontana, CA
Deron J Tessier, MD is a member of the following medical societies: American College of Surgeons and American Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Russell A Williams, MBBS, Program Director, Professor, Department of Surgery, University of California Medical Center at Irvine
Russell A Williams, MBBS is a member of the following medical societies: American College of Surgeons, American Pancreatic Association, Association for Surgical Education, Association of VA Surgeons, Society for Surgery of the Alimentary Tract, Southern California Society of Gastroenterology, and Southwestern Surgical Congress
Disclosure: Nothing to disclose.

Medical Editor

Juan B Ochoa, MD, Assistant Professor, Department of Surgery, University of Pittsburgh
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

David L Morris, MD, PhD, Professor, Department of Surgery, St George Hospital, University of New South Wales, Australia
Disclosure: Nothing to disclose.

CME Editor

Paolo Zamboni, MD, Professor of Surgery, Chief of Day Surgery Unit, Chair of Vascular Diseases Center, University of Ferrara, Italy
Paolo Zamboni, MD is a member of the following medical societies: American Venous Forum and New York Academy of Sciences
Disclosure: Nothing to disclose.

Chief Editor

John Geibel, MD, DSc, MA, Professor, Department of Surgery, Section of Gastrointestinal Medicine and Department of Cellular and Molecular Physiology, Yale University School of Medicine; Director of Surgical Research, Department of Surgery, Yale-New Haven Hospital
John Geibel, MD, DSc, MA is a member of the following medical societies: American Gastroenterological Association, American Physiological Society, American Society of Nephrology, Association for Academic Surgery, International Society of Nephrology, New York Academy of Sciences, and Society for Surgery of the Alimentary Tract
Disclosure: AMGEN Royalty Other; AMGEN Consulting fee Consulting

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.